- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02917772
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma (TITAN-RCC)
A Phase II Single Arm Clinical Trial of a Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Linz, Austria
- Ordensklinikum Linz Barmherzige Schwestern
-
Wien, Austria
- AKH Wien Universitätsklinik für Innere Medizin I
-
-
-
-
-
Antwerpen, Belgium
- ZNA Middelheim
-
Verviers, Belgium
- CHR Verviers
-
-
-
-
-
Hradec Králové, Czechia
- Fakultni nemocnice Hradec Kralove
-
Olomouc, Czechia
- Fakultni nemocnice Olomouc
-
Praha, Czechia
- FN Motol
-
Praha, Czechia
- Všeobecné fakultní nemocnice
-
-
-
-
-
La Roche-Sur-Yon, France
- CHD Vendee
-
Lyon, France
- Centre Hôpitalier Lyon Sud
-
Strasbourg, France
- Hôpitaux Universitaires de Strasbourg Hôpital Civil
-
Toulouse, France
- Institut Claudius Regaud
-
Villejuif, France
- Institut Gustave Roussy
-
-
-
-
-
Berlin, Germany
- Charité Universitätsmedizin Berlin
-
Dresden, Germany
- Universitätsklinikum Carl Gustav Carus
-
Düsseldorf, Germany
- Universitätsklinikum Düsseldorf
-
Düsseldorf, Germany
- Universitätsklinikum
-
Homburg/Saar, Germany
- Universität des Saarlandes Medizinische Fakultät
-
-
Thüringen
-
Jena, Thüringen, Germany, 07747
- Universitätsklinikum Jena und Poliklinik für Urologie
-
-
-
-
-
Arezzo, Italy
- Azienda USL8 Arezzo U.O.C. Oncologia Medica
-
Milano, Italy
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Pavia, Italy
- IRCCS Fondazione Policlinico San Matteo
-
Roma, Italy
- Policlinico Universitario A. Gemelli
-
Roma, Italy
- Azienda Ospedaliera San Camillo Forlanini
-
-
-
-
-
Barcelona, Spain
- Hospital de la Santa Creu i Sant Pau
-
Madrid, Spain
- Hospital Ramon y Cajal
-
Madrid, Spain
- Hospital 12 de Octubre
-
Oviedo, Spain
- Hospital Universitario Central de Asturias
-
Pamplona, Spain
- Complejo Hospitalario de Navarra
-
Santander, Spain
- Hospital Universitario Marqués de Valdecilla
-
Sevilla, Spain
- Hospital Virgen del Rocío
-
-
-
-
-
Chelmsford, United Kingdom
- Broomfield Hospital
-
London, United Kingdom
- Charing Cross Hospital
-
Maidstone, United Kingdom
- Kent Oncology Centre
-
Preston, United Kingdom
- Royal Preston Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Signed Written Informed Consent
- Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care.
- Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study.
Target Population
- Histological confirmation of RCC with a clear-cell component.
- Advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV) RCC
One (anti-angiogenic or temsirolimus) [to be eligible for 2nd line tier] or no prior systemic therapy for RCC [to be eligible for 1st line tier] with the following exception:
- One prior adjuvant or neoadjuvant therapy for completely resectable RCC if such therapy did not include an agent that targets VEGF or VEGF receptors as well as CTLA-4- or PD-1/PD-L1 immune checkpoint inhibitors, respectively, and if recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy.
- KPS of at least 70%
- Measurable disease as per RECIST v1.1
- Tumor tissue (FFPE archival or recent acquisition) must be received by the central vendor (block or unstained slides). (Note: Fine Needle Aspiration [FNA] and bone metastases samples are not acceptable for submission).
- Patients with intermediate and poor risk categories will be eligible for the study.
To be eligible as intermediate or poor-risk, at least one of the following prognostic factors as per the International Metastatic RCC Database Consortium (IMDC) criteria must be present:
- KPS equal to 70%
- Less than 1 year from initial diagnosis of RCC (eg, nephrectomy or first diagnostic biopsy) to registration (1st line) or to start of first-line targeted therapy (2nd line), respectively
- Hemoglobin less than the lower limit of normal (LLN)
- Corrected calcium concentration greater than the upper limit of normal (ULN)
- Absolute neutrophil count greater than the ULN
- Platelet count greater than the ULN
- If none of the above factors are present, subjects are not eligible (favorable-risk).
Age and Reproductive Status
- Males and Females, ≥ 18 years of age
- Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug.
- Women must not be breastfeeding
- Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception for a period of 30 days (duration of ovulatory cycle) plus the time required for the investigational drug to undergo five half-lives. The terminal half lives of nivolumab and ipilimumab are up to 25 days and 18 days, respectively. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug.
- Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for a period of 90 days (duration of sperm turnover) plus the time required for the investigational drug to undergo five half-lives. The terminal half lives of nivolumab and ipilimumab are up to 25 days and 18 days, respectively. Males who receive nivolumab combined with ipilimumab who are sexually active with WOCBP must continue contraception for 31 weeks (90 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug.
- Azoospermic males and WOCBP who are continuously not heterosexually active are exempt from contraceptive requirements. However, WOCBP must still undergo pregnancy testing as described in this section.
Exclusion Criteria:
Target Disease Exceptions
- Any history of or current CNS metastases. Baseline imaging of the brain by MRI (preferred) or CT scan is required within 28 days prior to registration.
Medical History and Concurrent Diseases
- Prior systemic treatment with more than one of the following drugs: mTOR, VEGF or VEGF receptor targeted therapy (including, but not limited to, temsirolimus, everolimus, sunitinib, pazopanib, axitinib, tivozanib, and bevacizumab).
- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
- Any active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids (> 10 mg daily prednisone equivalent) or immunosuppressive medications except for syndromes which would not be expected to recur in the absence of an external trigger. Subjects with vitiligo or type I diabetes mellitus or residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement are permitted to enroll.
- Any condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to first dose of study drug. Inhaled steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
- Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS).
- Any positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection.
- Known medical condition (eg, a condition associated with diarrhea or acute diverticulitis) that, in the investigator's opinion, would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results.
- Major surgery (eg, nephrectomy) less than 28 days prior to the first dose of study drug.
- Anti-cancer therapy less than 28 days prior to the first dose of study drug or palliative, focal radiation therapy less than 14 days prior to the first dose of study drug.
- Presence of any toxicities attributed to prior anti-cancer therapy, other than alopecia, that have not resolved to Grade 1 (NCI CTCAE v4) or baseline before administration of study drug.
- Physical and Laboratory Test Findings
Any of the following laboratory test findings:
- WBC < 2,000/mm3
- Neutrophils < 1,500/mm3
- Platelets < 100,000/mm3
- AST or ALT > 3 x ULN (> 5 x ULN if liver metastases are present)
- Total Bilirubin > 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
- Serum creatinine > 1.5 x upper limit of normal (ULN) or creatinine clearance < 40 mL/min (measured or calculated by Cockroft-Gault formula)
Allergies and Adverse Drug Reaction
- History of severe hypersensitivity reaction to any monoclonal antibody or any constituent of the product.
Other Exclusion Criteria
- Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts.
- Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nivolumab/Ipilimumab
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: until 30 weeks after last patient first treatment, LPFT
|
(RECIST 1.1) by CT or MRI measured at week 8 (+/- 1 week) and week 16 (+/- 1 week), 28 (+/- 1 week) and then every 12 weeks (+/- 1 week). The primary objective will be measured by the primary endpoint of ORR (based on investigator assessments) among all treated subjects, first line subjects and second line subjects. It is defined as the number of subjects with a best overall response of CR or PR divided by the number of all treated subjects, first line subjects or second line subjects. Best overall response is defined as the best response designation, as determined by investigator, recorded between the date of first dose and the date of objectively documented immunotherapy resistance per RECIST v1.1 or the date of subsequent therapy, whichever occurs first. For subjects without documented immunotherapy refractory disease or subsequent therapy, all available response designations will contribute to the ORR determination. |
until 30 weeks after last patient first treatment, LPFT
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
General considerations: RR, TTR, DoR, PFS, TIR (Time to Immunotherapy Resistance), OS
Time Frame: until 30 weeks after last patient first treatment, LPFT
|
All as assessed by investigators among all treated subjects, first line subjects, and second line subjects.
Furthermore, patients with IMDC intermediate and high risk will be analysed separately.
|
until 30 weeks after last patient first treatment, LPFT
|
Remission Rates during TITAN treatment: RR1, RR2, RR2SD, RR3
Time Frame: until 30 weeks after last patient first treatment, LPFT
|
|
until 30 weeks after last patient first treatment, LPFT
|
Time to Immunotherapy Resistance: TIR
Time Frame: Time from first dosing date to the date of documented tumor progression based on investigator assessments (per RECIST 1.1) despite 4 "boost" cycles or within 3 months after the last "boost" cycle, or death due to any cause.
|
Subjects with disease progression despite 4 nivolumab/ipilimumab combination "boost" cycles or within 3 months after the last "boost" cycle will be considered immunotherapy resistant.
|
Time from first dosing date to the date of documented tumor progression based on investigator assessments (per RECIST 1.1) despite 4 "boost" cycles or within 3 months after the last "boost" cycle, or death due to any cause.
|
Time-to-Response: TTR
Time Frame: Time from first dosing date or initiation of nivolumab/ipilimumab "boost" cycles to the date of the first confirmed response thereafter, as assessed by the IRC.
|
TTR may be recorded several times per patient.
|
Time from first dosing date or initiation of nivolumab/ipilimumab "boost" cycles to the date of the first confirmed response thereafter, as assessed by the IRC.
|
Duration of Response: DOR
Time Frame: Time from first confirmed response (CR or PR) to the date of the documented progressive disease as determined using RECIST 1.1 criteria or death due to any cause, whichever occurs first.
|
DOR may be recorded multiple times per patient.
|
Time from first confirmed response (CR or PR) to the date of the documented progressive disease as determined using RECIST 1.1 criteria or death due to any cause, whichever occurs first.
|
Overall survival:OS
Time Frame: Time from first dosing date to the date of death. A subject who has not died will be censored at last known date alive.
|
OS is defined as the time from first dosing date to the date of death.
A subject who has not died will be censored at last known date alive.
|
Time from first dosing date to the date of death. A subject who has not died will be censored at last known date alive.
|
Safety: Adverse events assessment
Time Frame: Continuously: Treatment Visit day 1/week 1 until Survival Visits/Follow-up Visits
|
Treatment Emergent Adverse Events according to CTC 4
|
Continuously: Treatment Visit day 1/week 1 until Survival Visits/Follow-up Visits
|
Safety: Frequency of abnormal laboratory parameters
Time Frame: Screening Visit until Survival Visits/Follow-up Visits
|
Treatment Period: Within 72 hrs prior to re-dosing to include CBC w/ differential, AST, ALT, ALP, T.Bili, BUN or serum urea level, creatinine. Ca, Mg, Na, K, Cl, LDH, glucose, amylase, lipase, TSH (with reflexive Free T4 and Free T3). Follow-up Period: On site/local CBC w/differential, AST, ALT, ALP, T.Bili, BUN or serum urea level, creatinine and TSH for X01, repeat at X02 if study drug related toxicity persists. |
Screening Visit until Survival Visits/Follow-up Visits
|
Patient reported outcomes
Time Frame: Treatment Visit day 1/week 1 until Survival Visits/Follow-up Visits 1 and 2
|
NCCN-FACT FKSI-19 (Version 2)
|
Treatment Visit day 1/week 1 until Survival Visits/Follow-up Visits 1 and 2
|
Exploratory objectives: Immune monitoring
Time Frame: Taken together with Laboratory Tests: Prior to induction (Baseline), Prior to Nivo dose 4, Prior to Nivo dose 8, Prior to 6th nivo maintenance dosing
|
|
Taken together with Laboratory Tests: Prior to induction (Baseline), Prior to Nivo dose 4, Prior to Nivo dose 8, Prior to 6th nivo maintenance dosing
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Marc-Oliver Grimm, Prof., Universitätsklinikum Jena
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
- Ipilimumab
Other Study ID Numbers
- 0216-ASG
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Renal Cell
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Australian and New Zealand Urogenital and Prostate...RecruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell CarcinomaAustralia
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell CarcinomaUnited States
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRecruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell CarcinomaUnited States, Taiwan, Australia
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWithdrawnMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingChromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...United States
-
Australian and New Zealand Urogenital and Prostate...Bristol-Myers SquibbActive, not recruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation CarcinomaAustralia
-
Peloton Therapeutics, Inc.Active, not recruitingKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, RecurrentUnited States
-
AmgenCompletedRenal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Clear Cell Renal Carcinoma | Renal Cell AdenocarcinomaFrance, United States, Germany
Clinical Trials on Nivolumab/Ipilimumab
-
Bristol-Myers SquibbCompletedLung CancerItaly, United States, France, Russian Federation, Spain, Argentina, Belgium, Brazil, Canada, Chile, Czechia, Germany, Greece, Hungary, Mexico, Netherlands, Poland, Romania, Switzerland, Turkey, United Kingdom
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingHepatocellular Carcinoma (HCC)Taiwan
-
Ontario Clinical Oncology Group (OCOG)Bristol-Myers SquibbActive, not recruitingMetastatic Renal Cell CarcinomaCanada, Australia
-
Bristol-Myers SquibbCompletedCarcinoma, Renal CellUnited States, Italy, Brazil, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, France, Germany, Japan, Mexico, Netherlands, Poland, Romania, Russian Federation, Singapore, Spain, Switzerland, Turkey, United...
-
Baptist Health South FloridaBristol-Myers Squibb; NovoCure Ltd.TerminatedRecurrent GlioblastomaUnited States
-
Italian Network for Tumor Biotherapy FoundationBristol-Myers Squibb; Astex Pharmaceuticals, Inc.Not yet recruitingMelanoma | Non Small Cell Lung CancerItaly
-
Universitätsklinikum KölnZKS KölnWithdrawnCervical Cancer ≥ FIGO IIB and or Lymph Node Metastases
-
Jason J. Luke, MDArray BioPharmaActive, not recruitingMelanoma | Renal Cell Carcinoma | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell CarcinomaUnited States
-
Italian Network for Tumor Biotherapy FoundationBristol-Myers SquibbUnknown
-
GERCOR - Multidisciplinary Oncology Cooperative...Bristol-Myers SquibbRecruitingColorectal Cancer Metastatic | MSI-H Colorectal CancerFrance